Thymalin: side effects and evidence limits
The Thymalin listing describes a thymus polypeptide fraction supplied as lyophilized powder [1]. In the inspected comparative abstract, Thymalin is a calf-thymus extract distinct from synthetic Thymogen and Vilon [2]. These materials and thymosin-alpha-1 must not be substituted for one another.
The inspected cell-study methods name Thymalin/P4 as a calf-thymus peptide complex. Human THP-1 leukemia-derived cultures received 100 ng/mL overnight; differentiated macrophage experiments used 2–12-hour windows. Viability and cellular signaling were assessed, rather than clinical adverse reactions [3].
Human-derived cells are not people receiving the preparation. The inspected sections do not supply a clinical reaction frequency for the current powder, whose equivalence to the study fraction remains unverified. These cell findings do not establish clinical product safety or replace causal assessment of adverse events [1–3].
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Clinical reaction frequency for the current powder | Cell study: human THP-1 leukemia-derived cultures, calf-thymus peptide complex at 100 ng/mL overnight | Viability and cellular signaling were assessed rather than clinical adverse reactions; human-derived cells are not people receiving the preparation, and equivalence of the current powder to the study fraction remains unverified | [1–3] |
References
- Longeva (2026). Thymalin https://longeva.bio/ua/product/tymalin.
- Morozov VG; Khavinson VK (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. https://pubmed.ncbi.nlm.nih.gov/9637345/ doi:10.1016/s0192-0561(97)00058-1.
- Avolio F et al. (2022). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. https://pubmed.ncbi.nlm.nih.gov/35408963/ doi:10.3390/ijms23073607.